Preclinical News and Research

RSS
Abstract submissions, registration now open for 2nd International Symposium on MR-guided Focused Ultrasound

Abstract submissions, registration now open for 2nd International Symposium on MR-guided Focused Ultrasound

6-month results of NovoStent's SAMBA trial for atherosclerotic disease in SFA and popliteal arteries

6-month results of NovoStent's SAMBA trial for atherosclerotic disease in SFA and popliteal arteries

Highlights from June 2010 issue of American Journal of Pathology

Highlights from June 2010 issue of American Journal of Pathology

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

Five Prime Therapeutics, Fast Forward partner to develop Multiple Sclerosis therapeutic candidate

CoDa Therapeutics reports positive results from Phase 2 study of NEXAGON for chronic venous leg ulcers

CoDa Therapeutics reports positive results from Phase 2 study of NEXAGON for chronic venous leg ulcers

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

Nanoliposomes engineered to deliver therapeutic drugs that kill malignant cells

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Spectrum Pharmaceuticals to present clinical data on belinostat at ASCO 2010

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Yissum introduces Dralgo platform to accelerate discovery of promising drug candidates

Yissum introduces Dralgo platform to accelerate discovery of promising drug candidates

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

t2c001 product obtains certificate under EMA regulations for ATMPs

t2c001 product obtains certificate under EMA regulations for ATMPs

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

ADDF provides $248,000 grant to ALSP to allow its lead drug candidate towards clinical trials

ADDF provides $248,000 grant to ALSP to allow its lead drug candidate towards clinical trials

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

Sinapis Pharma completes Bridge financing to continue support drug development program

Sinapis Pharma completes Bridge financing to continue support drug development program

Thymosin beta 4 reduces brain tissue damage, improves brain function in rats: Research paper

Thymosin beta 4 reduces brain tissue damage, improves brain function in rats: Research paper

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Sangamo's ZFP Therapeutics technology highlighted at ASGCT Annual Meeting

Phase 1 clinical trial of OXY111A initiated

Phase 1 clinical trial of OXY111A initiated

Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA

Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA

Cell Therapeutics signs agreement to sell $21.0M of shares of Series 5 Preferred Stock

Cell Therapeutics signs agreement to sell $21.0M of shares of Series 5 Preferred Stock

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.